Dekavil (F8IL10) is a fully-human anti-inflammatory product consisting of the F8 antibody fused to interleukin-10 (IL10). The fusion to the F8 antibody, which is specific to the EDA domain of fibronectin generates a product, which selectively localizes in the inflamed tissue of various inflammatory conditions.
Dekavil has demonstrated a striking in vivo activity in various models of chronic inflammation and in a Phase I study in last line patients with Rheumatoid Arthritis.
The product is partnered and is investigated in phase II clinical studies for the treatment of chronic inflammatory disorders.
EULAR conferences 2013, 2014, 2015
Doll et al., (2013) Arthritis Res Ther, 15, R13826, 2344-52
Schwager et al., (2011) Human Reprod, 26, 2344-52
Schwager et al., (2009) Arthritis Res Ther, 11, R142
Trachsel et al., (2007) Arthritis Res Ther, 9, R9
Trachsel et al., (2007) J Invest Dermatol, 127, 881-6